Citations

Showing 10 of 107966 citations.

Should Older Patients Accept a High Kidney Donor Profile Index Kidney or Wait? A National Data Analysis of Matched Cohorts
Jarmi, Tambi , Attieh, Rose Mary , Green, Shawna , Spaulding, Aaron C. , Brennan, Emily , Spaulding, Aaron , Vargas, Emily , Green, Shawna M , Spaulding, Aaron C , Spaulding, Aaron , Jarmi, Tambi , Brennan, Emily

Mayo Clinic

Annals of Surgery | March 13, 2025 | Volume: 284 | Issue: 2 | Pages: 328-335

10.1097/sla.0000000000006695 | PMID 40079148 Get It

Objective: To address whether kidney transplant (KTx) candidates, ages 60+, should accept a high Kidney Donor Profile Index (KDPI) kidney and differences when considering a high (>85%) versus low (<85%) KDPI KTx. Background: To date, there is limited survival data to guide decision-making for patients aged ≥60 years who are faced with the choice of accepting a high KDPI kidney or remaining on the waitlist. Methods: Propensity-matched cohort study using data from United Network on Organ Sharing (2014–2021). Cox proportional hazard models and competing risk models allowed comparison of (1) patient survival on the waitlist or after KTx and (2) patient and graft survival after KTx for the second comparison between matched groups, stratified by age groups: 60 to 65, 66 to 70, and 71+. Results: Receiving a >85% KDPI kidney versus remaining on the waitlist was associated with reduced mortality [Hazard Ratio (HR): 0.68, 95% CI: 0.59–0.80, P < 0.001] overall and across the 2 oldest age groups: 66 to 70 (HR: 0.57, 95% CI: 0.44–0.73, P < 0.001) and 71+ (HR: 0.59, 95% CI: 0.44–0.83, P < 0.001). Those aged 60 to 65 did not experience a survival benefit (HR: 0.86, 95% CI: 0.67–1.11, P = 0.259). Patients ages 60+ receiving a >85% or ≤85% KDPI kidney experience comparable survival rates. Conclusions: Our study revealed a survival advantage linked to receiving a lower-quality KTx than remaining on the waitlist in the overall sample and for those 66+. Graft failure and survival were independent of the organ quality.
Acute Intracerebral Hemorrhage Associated with Extensive Venous Thrombosis Due to Spontaneous Heparin-Induced Thrombocytopenia After Total Knee Replacement: A Case Report
Kashani, Mehdi , Brown, Meghan A. , Graces, Juan Pablo Domecq, Domecq Graces, Juan Pablo , Brown, Meghan

Mayo Clinic

Hematology Reports | March 13, 2025 | Volume: 17 | Issue: 2 | Pages: 12

10.3390/hematolrep17020012 | PMID 40126221 Get It

Introduction: Heparin-induced thrombocytopenia (HIT) is an autoimmune life-threatening prothrombotic syndrome associated with low platelet count after heparin exposure. Spontaneous heparin-induced thrombocytopenia (S-HIT) is an even less frequent variant of HIT, with only a handful of reports available in the literature, where unexplained thrombocytopenia and/or thrombosis without recent heparin exposure occurs in the setting of positive anti-PF4 antibodies. Case Presentation: We report a case of S-HIT associated with pulmonary artery embolism, left internal jugular vein, and cerebral vein sinus thrombosis complicated with ipsilateral acute intracerebral hemorrhage. Discussion: It is important to highlight that in patients with otherwise unexplained thrombocytopenia and prior exposure to an inflammatory process, S-HIT should be on the differential. Conclusions: Recognition and avoidance of heparin exposure is the most important aspect of S-HIT, as the management is otherwise similar to HIT.
Assessment of Left‐Sided Hemodynamics With Exercise in Patients With Continuous Flow Left Ventricular Assist Device Support
Inglis, Sara S. , Schettle, Sarah , Villavicencio, Mauricio A. , Spencer, Philip J. , Stulak, John M., Kushwaha, Sudhir S. , Behfar, Atta, Rosenbaum, Andrew , Schettle, Sarah D , Rosenbaum, Andrew N , Inglis, Sara S , Tang, Paul C. , Behfar, Atta

Mayo Clinic

Artificial Organs | March 13, 2025 | Volume: 49 | Issue: 9 | Pages: 1462-1469

10.1111/aor.14995 | PMID 40078038 Get It

ABSTRACT Background Addition of left heart catheterization (LHC) to exercise protocols allows for a unique focus on parameters of systolic and diastolic responses to increased activity in patients with left ventricular assist device (LVAD) support. Methods A retrospective review was conducted of all consecutive adult patients who underwent LHC with exercise for any indication from June 2017 to June 2023. For all patients, the relationship between exercise and parameters of LV systolic and diastolic response was assessed. Patients were divided into two cohorts based on the indication for testing: hemodynamic optimization (Optim, n = 5) or weaning consideration (Wean, n = 3). Results Eight patients (88% male, median age 57 years (IQR 44, 65)) were included. LVEF was 45% (IQR 45, 56) in Wean and 25% (IQR 20, 42) in Optim. LV systolic work index (LVSWI) increased more rapidly over levels of exercise in Wean vs. Optim (slope 46.3 vs. −0.625; p = 0.044) and LVSWI rose more quickly at lower levels of LV end diastolic pressure (LVEDP) in Wean vs. Optim (slope 219.5 vs. −2.008; p = 0.0026). Pulse power index was higher in Wean patients at baseline (0.046 (IQR 0.04, 0.07) vs. 0.016 (IQR 0.001, 0.04); p = 0.14) and peak exercise (0.12 (IQR 0.12, 0.12) vs. 0.06 (IQR 0.03, 0.1); p = 0.29). Conclusions Patients with favorable remodeling on LVAD support have significantly improved LV systolic and diastolic responses to exercise and a trend of higher systemic pulsatility. Improving our understanding of LV‐LVAD interactions with activity may aid in future efforts to improve exercise tolerance through speed modulation.
Seizures Associated with Autoimmune Disorders — Current Treatment Approaches
Gillinder, Lisa , Britton, Jeffrey W.

Mayo Clinic

Seminars in Neurology | March 13, 2025 | Volume: 45 | Issue: 02 | Pages: 275-286

10.1055/a-2525-3511 | PMID 40074214 Get It

AbstractAutoimmune-associated seizures and epilepsy are increasingly recognized in clinical practice and can arise in the setting of acute encephalitis but in some cases may present with chronic focal epilepsy. These conditions are usually resistant to antiseizure therapy but may respond definitively to timely immunotherapy. Early diagnosis and treatment are critical to minimize neural injury and optimize outcomes. Treatment is guided by consensus opinion because definitive trials are currently lacking. The initial management approach usually involves first-line agents such as corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange, with second-line agents like rituximab or cyclophosphamide. Maintenance therapy is considered to prevent relapses, which occur in up to 35% of patients. Relapse management requires careful differentiation from postencephalitic epilepsy, which in the absence of active inflammation does not respond to immunotherapy. This review discusses treatment strategies for autoimmune-associated seizure disorders, including acute symptomatic seizures and epilepsy. We discuss expected outcomes on the basis of the underlying pathogenesis including cases mediated by autoantibodies targeting specific neuronal surface/synaptic antigens, and intracellular epitopes, and for cases lacking defined biomarkers. Specific approaches are outlined for disorders such as anti-LGI1, anti-NMDAR, anti-GABA-BR, and anti-GAD65 encephalitides, emphasizing tailored immunotherapy based on pathophysiology and clinical context.
Advancing Metastatic Spine Tumor Research: A Review of AO Spine Knowledge Forum Tumor’s Scientific Contributions Derived From the EPOSO Network, 2014-2024
Rutges, Joost , Fehlings, Michael G. , Gokaslan, Ziya L., Rhines, Laurence D. , Sahgal, Arjun , Sciubba, Daniel M. , Schuster, James M. , Weber, Michael H. , Laufer, Ilya , Fisher, Charles G. , Tumor, on the behalf of the AO Spine Knowledge Forum, Rutges, Joost P H J , Fehlings, Michael G , Rhines, Laurence D , Zuckerman, Scott L. , Arnold, Paul M. , Bettegowda, Chetan , Boriani, Stefano , Clarke, Michelle J. , Lazáry, Áron , Tumor, on the behalf of the AO Spine Knowledge Forum

Mayo Clinic

Global Spine Journal | March 12, 2025 | Volume: 15 | Issue: 6 | Pages: 2999-3006

10.1177/21925682251326515 | PMID 40074676 Get It

Study Design Narrative Review. Objectives To summarize the work of the AO Spine Knowledge Forum Tumor, specifically studies from the Epidemiology, Process and Outcomes in Spine Oncology (EPOSO) study. Methods A narrative review of all published manuscripts from the EPOSO study was undertaken. EPOSO represents a multicenter, prospective registry effort across 10 North American and European sites to enroll patients with metastatic disease of the spine. Results The current review summarized all studies from the EPOSO network, divided into the following five sections: (1) quality of life and satisfaction, (2) overall survival, (3) spinal instability, (4) neurologic outcome in patients with metastatic epidural spinal cord compression or radicular pain, and (5) patient and tumor-specific factors. Several important findings were elucidated. Patient evaluation should include SINS, nutritional status, severity and duration of neurologic deficit, extent of metastatic tumor burden, and differentiation of axial from radicular pain. Moreover, SOSGOQ2.0 serves as a useful and validated instrument for patient-reported outcome instrument. Despite the palliative nature of metastatic spine surgery, clear improvement in quality-of-life is seen. Even in patients with short-survival, the remaining weeks and months of life result in improved quality-of-life. Metastatic spine surgery often improves neurologic function, potentially enhancing survival through increased performance status. Conclusions Several noteworthy results have come from the EPOSO network, highlighting important trends in metastatic spine care. The AO Spine Knowledge Forum Tumor has helped advancing metastatic spine tumor research as well as ensure these new findings reach and benefit clinicians and their patients.
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+
Sklavenitis‐Pistofidis, Romanos , Lightbody, Elizabeth D. , Reidy, Mairéad, Tsuji, Junko , Alberge, Jean-Baptiste , Aranha, Michelle P. , Heilpern-Mallory, Daniel , Huyng, Daisy, Chong, Stephen Jun Fei , Chung, Anna Y., Zhang, Jeremy, Hackett, Liam , Wu, Ting , Berrios, Brianna, Belkin, Saveliy , Dutta, Ankit K. , Knudson, Ryan A., Brandt, Carolyn, Papaioannou, Maria , Manier, Salomon , Hackett, Liam , Haradhvala, Nicholas J , Wu, Ting , Su, Nang K , Belkin, Saveliy , Dutta, Ankit K , Greipp, Patricia T , Ghobrial, Irene M , Manier, Salomon , Sklavenitis-Pistofidis, Romanos , Alberge, Jean-Baptiste , Roweth, Harvey G. , Huynh, Daisy , Chung, Anna Y., Su, Nang Kham , Brandt, Carolyn, Greipp, Patricia T. , Davids, Matthew S. , Getz, Gad , Ghobrial, Irene M.

Mayo Clinic

Blood | March 12, 2025 | Volume: 146 | Issue: 1 | Pages: 89-103

10.1182/blood.2024025102 | PMID 40073369 Get It

Abstract The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.
Altered Bile Acids and Pouch Microbiota Composition in Patients With Chronic Pouchitis
Dunleavy, Katie A. , Camilleri, Michael , Raffals, Laura E. , Dunleavy, Katie , Raffals, Laura

Mayo Clinic

Inflammatory Bowel Diseases | March 12, 2025 | Volume: 31 | Issue: 4 | Pages: 1184-1187

10.1093/ibd/izaf005 | PMID 40073325 Get It

Lay Summary This article looks at how changes in bile acids and gut bacteria might contribute to chronic pouchitis, a condition that can develop after surgical removal of the colon and creation of a J-pouch for people with inflammatory bowel disease. The goal is to better understand pouchitis and find treatments to improve patients’ health.
Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study
Herrmann, Ken, Krause, Bernd‐Joachim, Chi, K.N., Fizazi, Karim , Eiber, M., Jentzen, Walter, Nguyen, Quang Ngoc , Blumenstein, Lars, Wilke, C., Sartor, Oliver , Morris, Michael J. , Bono, Johann S. de , Tagawa, Scott T. , Kurth, Jens , Laßmann, Michael , Sparks, R, Nguyen, Q, Rahbar, Kambiz

Mayo Clinic

Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 49-49

10.1055/s-0045-1804292 Get It

Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Fizazi, Karim , Shore, N., Chi, K.N., Crosby, M. J., Roubaud, Guilhem, Fleming, Mark T. , Nordquist, L., Gauna, D.E. Castellano, Carnahan, Natalie, Ghebremariam, Samson, Hertelendi, Marianna , Eiber, Matthias , Morris, Michael J. , Bono, Johann S. de , Hermann, Ken , Nagarajah, James , Lewis, Brian E. , Sartor, Oliver

Mayo Clinic

Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 45-46

10.1055/s-0045-1804283 Get It

Evaluating the Impact of Capsular Closure on Clinical Outcomes, Revision Rates, and Return to Sports in Adolescent Females Undergoing Hip Arthroscopy for Femoroacetabular Impingement
Vera, Angelina M., McQuivey, Kade S. , Murphy, Sierra , Brinkman, Joseph C. , Economopoulos, Kostas J. , Murphy, Sierra N, Economopoulos, Kostas J

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 12, 2025 | Volume: 13 | Issue: 3 | Pages: No page available

10.1177/23259671241295755 | PMID 40083751 Get It

Background: Young female patients undergoing hip arthroscopy have an increased prevalence of baseline capsular laxity of the hip joint. This laxity, along with superimposed postoperative iatrogenic capsular deficiency secondary to an unrepaired capsule, could potentially lead to worse outcomes after arthroscopic treatment of femoroacetabular impingement (FAI) in this population. Purpose: To compare outcomes and revision rates for young female patients undergoing hip arthroscopy for FAI and labral tear with capsular closure (CC group) versus capsular nonclosure (CNC group). Study Design: Cohort study; Level of evidence, 3. Methods: A retrospective review of prospectively collected data of patients who underwent index hip arthroscopy using interportal capsulotomies by a single surgeon between January 2014 and February 2020 was performed. Female patients aged 12 to 21 years who underwent hip arthroscopy with cam or pincer osteoplasty and labral repair with a 2-year minimum follow-up were included. The Beighton score was assessed. The Hip Outcome Score–Activities of Daily Living (HOS-ADL) and Hip Outcome Score–Sport-Specific Subscale (HOS-SSS) were obtained preoperatively and at 3 months, 1 year, and 2 years postoperatively. Data were analyzed using the Mann-Whitney U test and Fisher exact test. Results: A total of 23 hips (20 patients) were included in the CC group and 17 hips (16 patients) were included in the CNC group. The groups were not different regarding characteristics and preoperative patient-reported outcome scores. At all follow-up intervals postoperatively, the CC group scored significantly higher HOS-ADL and HOS-SSS. Fifteen of 17 (88.2%) patients in the CC group returned to sports versus 8 of 14 (57.1%) in the CNC group ( P = .03). Four (17.4%) hips in the CC group had revision surgery compared with 9 (52.9%) hips in the CNC group (odds ratio, 5.1; 95% CI, 1.2-22.5; P = .02). Conclusion: Young female patients treated with CC while undergoing arthroscopic FAI had improved outcomes, fewer revisions, and a higher return-to-sports rate than those treated without CC.